Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name RET rearrange
Gene Variant Detail

RET rearrange (unknown)

Relevant Treatment Approaches RET Inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05313009 Phase Ib/II Sotorasib + TH-4000 Tarlox and Sotorasib in Patients With KRAS G12C Mutations Terminated USA 0
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT03178552 Phase II Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Atezolizumab + Cobimetinib + Vemurafenib Alectinib A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST) Recruiting USA | NZL | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT01813734 Phase II Ponatinib Ponatinib in Advanced NSCLC w/ RET Translocations Completed USA 0
NCT05241873 Phase Ib/II BLU-451 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Active, not recruiting USA | CAN 3
NCT01877083 Phase II Lenvatinib Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed USA 4
NCT03194893 Phase III Crizotinib Alectinib A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer Recruiting USA | ITA | FRA | ESP 6
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed USA 0
NCT04211337 Phase III Vandetanib Cabozantinib Selpercatinib A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT05048797 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT 11
NCT05469178 Phase Ib/II Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer Recruiting USA 0
NCT06119581 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT04131543 Phase II Cabozantinib Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) Unknown status ITA 0
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT05255302 Phase II Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL) Recruiting FRA 0
NCT03131206 Phase Ib/II Alectinib A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer Terminated USA 0
NCT05815186 Phase II Ladarixin + Sotorasib Ladarixin With Sotorasib in Advanced NSCLC - Phase II Withdrawn USA 0
NCT05555732 Phase III Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15
NCT05215340 Phase III Pembrolizumab Datopotamab deruxtecan + Pembrolizumab Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 17
NCT05589818 Phase II Pembrolizumab Pembrolizumab for Advanced NSCLC and PS 2-3 Recruiting USA 0
NCT04984811 Phase II Atezolizumab + NT-I7 NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Active, not recruiting USA 0
NCT05401786 Phase II Cemiplimab Ipilimumab Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) Recruiting NLD 0
NCT05240131 Phase Ib/II Atezolizumab + GB1211 A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). Active, not recruiting FRA | ESP 1
NCT05777603 Phase I Aztreonam + Pembrolizumab + Vancomycin Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Recruiting USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT06074588 Phase III Docetaxel SKB264 Pemetrexed Disodium MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) Recruiting USA | CAN | AUS 8
NCT06007924 Phase II Defactinib + RO5126766 A Study of Avutometinib and Defactinib in People With Thyroid Cancer Recruiting USA 0
NCT06094296 Phase II Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Recruiting USA | ITA | FRA | ESP | AUS 4
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed USA 0
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT05815173 Phase I Ladarixin + Sotorasib Ladarixin With Sotorasib in Advanced NSCLC Recruiting USA 0
NCT05153408 Phase Ib/II BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Terminated USA 0
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT03037385 Phase Ib/II Pralsetinib Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL 5
NCT04866017 Phase III Durvalumab BGBA1217 + Tislelizumab Tislelizumab A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Terminated USA | AUS 2
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Terminated 1
NCT05541822 Phase II ABN401 To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation Recruiting USA 2
NCT01829217 Phase II Sunitinib Sunitinib in Never-Smokers With Lung Adenocarcinoma Completed USA 0
NCT05788926 Phase I TG6050 A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) Recruiting FRA 0
NCT01831726 Phase II Dovitinib Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Completed USA 0